Cargando…
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has raised attention as a novel anticancer therapeutic as it induces apoptosis preferentially in tumor cells. However, first-generation TRAIL-receptor agonists (TRAs), comprising recombinant TRAIL and agonistic receptor-specific antibod...
Autores principales: | Legler, Karen, Hauser, Charlotte, Egberts, Jan-Hendrik, Willms, Anna, Heneweer, Carola, Boretius, Susann, Röcken, Christoph, Glüer, Claus-Christian, Becker, Thomas, Kluge, Michael, Hill, Oliver, Gieffers, Christian, Fricke, Harald, Kalthoff, Holger, Lemke, Johannes, Trauzold, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906476/ https://www.ncbi.nlm.nih.gov/pubmed/29670075 http://dx.doi.org/10.1038/s41419-018-0478-0 |
Ejemplares similares
-
Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC
por: Gundlach, Jan-Paul, et al.
Publicado: (2018) -
Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
por: Merz, Christian, et al.
Publicado: (2015) -
Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma
por: Will, Olga Maria, et al.
Publicado: (2016) -
TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
por: Mert, Ufuk, et al.
Publicado: (2019) -
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model
por: Fritsche, Hendrik, et al.
Publicado: (2015)